Medivir AB’s Partner GlaxoSmithKline Initiates OTC Launch of Xerclear® in Europe under Trade Names Zoviduo and Zovirax Duo

Published: Feb 08, 2012

HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News:

Medivir AB (STO:MVIRB), the research-based specialty pharmaceutical company focused on infectious diseases, announces that its unique cold sore product Xerclear®, which Medivir developed in-house, is now being launched for over-the-counter (OTC) use by its partner GlaxoSmithKline (GSK) in Europe. Xerclear® will be marketed under the trade name Zoviduo and Zovirax Duo in Europe.

Back to news